A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark. / O’Regan, Elisabeth; Svalgaard, Ingrid Bech; Sørensen, Anna Irene Vedel; Spiliopoulos, Lampros; Bager, Peter; Nielsen, Nete Munk; Hansen, Jørgen Vinsløv; Koch, Anders; Meder, Inger Kristine; Videbech, Poul; Ethelberg, Steen; Hviid, Anders.
In: npj Vaccines, Vol. 9, No. 1, 52, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark
AU - O’Regan, Elisabeth
AU - Svalgaard, Ingrid Bech
AU - Sørensen, Anna Irene Vedel
AU - Spiliopoulos, Lampros
AU - Bager, Peter
AU - Nielsen, Nete Munk
AU - Hansen, Jørgen Vinsløv
AU - Koch, Anders
AU - Meder, Inger Kristine
AU - Videbech, Poul
AU - Ethelberg, Steen
AU - Hviid, Anders
N1 - Publisher Copyright: © The Author(s) 2024.
PY - 2024
Y1 - 2024
N2 - Many individuals who refuse COVID-19 vaccination have concerns about long-term side effects. Here, we report findings on self-reported symptoms from a Danish survey- and register study. The study included 34,868 vaccinated primary course recipients, 95.8% of whom received mRNA vaccines, and 1,568 unvaccinated individuals. Participants had no known history of SARS-CoV-2 infection. Using g-computation on logistic regression, risk differences (RDs) for symptoms between vaccinated and unvaccinated persons were estimated with adjustments for possible confounders. Within six weeks after vaccination, higher risks were observed for physical exhaustion (RD 4.9%, 95% CI 1.1% to 8.4%), fever or chills (RD 4.4%, 95% CI 2.1% to 6.7%), and muscle/joint pain (RD 7.0%, 95% CI 3.1% to 10.7%), compared to unvaccinated individuals. Beyond twenty-six weeks, risks were higher among the vaccinated for sleeping problems (RD 3.0, 95% 0.2 to 5.8), fever or chills (RD 2.0, 95% CI 0.4 to 3.6), reduced/altered taste (RD 1.2, 95% CI 0.2 to 2.3) and shortness of breath (RD 2.6, 95% CI 0.9 to 4.0). However, when examining pre-omicron responses only, the difference for reduced/altered taste was significant. As expected, the risk of experiencing physical exhaustion, fever or chills, and muscle/joint pain was higher among persons who responded within six weeks of completing the primary course. No significant differences were observed for the 7-25-week period after vaccination. Associations for the period beyond 26 weeks must be interpreted with caution and in the context of undetected SARS-CoV-2 infection, wide confidence intervals, and multiple testing. Overall, we observe no concerning signs of long-term self-reported physical, cognitive, or fatigue symptoms after vaccination.
AB - Many individuals who refuse COVID-19 vaccination have concerns about long-term side effects. Here, we report findings on self-reported symptoms from a Danish survey- and register study. The study included 34,868 vaccinated primary course recipients, 95.8% of whom received mRNA vaccines, and 1,568 unvaccinated individuals. Participants had no known history of SARS-CoV-2 infection. Using g-computation on logistic regression, risk differences (RDs) for symptoms between vaccinated and unvaccinated persons were estimated with adjustments for possible confounders. Within six weeks after vaccination, higher risks were observed for physical exhaustion (RD 4.9%, 95% CI 1.1% to 8.4%), fever or chills (RD 4.4%, 95% CI 2.1% to 6.7%), and muscle/joint pain (RD 7.0%, 95% CI 3.1% to 10.7%), compared to unvaccinated individuals. Beyond twenty-six weeks, risks were higher among the vaccinated for sleeping problems (RD 3.0, 95% 0.2 to 5.8), fever or chills (RD 2.0, 95% CI 0.4 to 3.6), reduced/altered taste (RD 1.2, 95% CI 0.2 to 2.3) and shortness of breath (RD 2.6, 95% CI 0.9 to 4.0). However, when examining pre-omicron responses only, the difference for reduced/altered taste was significant. As expected, the risk of experiencing physical exhaustion, fever or chills, and muscle/joint pain was higher among persons who responded within six weeks of completing the primary course. No significant differences were observed for the 7-25-week period after vaccination. Associations for the period beyond 26 weeks must be interpreted with caution and in the context of undetected SARS-CoV-2 infection, wide confidence intervals, and multiple testing. Overall, we observe no concerning signs of long-term self-reported physical, cognitive, or fatigue symptoms after vaccination.
U2 - 10.1038/s41541-024-00844-w
DO - 10.1038/s41541-024-00844-w
M3 - Journal article
C2 - 38438399
AN - SCOPUS:85186860991
VL - 9
JO - npj Vaccines
JF - npj Vaccines
SN - 2059-0105
IS - 1
M1 - 52
ER -
ID: 385568586